Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial
First and only next-generation oral SERD and complete ER antagonist to demonstrate consistent progression-free survival benefit in combination with widely approved CDK4/6 inhibitors in 1st-line advanced breast cancer
WILMINGTON, Del., June 01, 2025--(BUSINESS WIRE)--Positive results from the SERENA-6 Phase III trial showed that AstraZeneca's camizestrant in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS). The trial evaluated switching to the camizestrant combination versus continuing standard-of-care treatment with an aromatase inhibitor (AI) (anastrozole or letrozole) in combination with a CDK4/6 inhibitor in the 1st-line treatment of patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.
These results will be presented today during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL (abstract #LBA4) and simultaneously published in The New England Journal of Medicine.
Results showed the camizestrant combination reduced the risk of disease progression or death by 56% compared to standard-of-care treatment (based on a hazard ratio [HR] of 0.44; 95% confidence interval [CI] 0.31–0.60; p<0.00001) as assessed by investigator. Median PFS was 16.0 months for patients who switched to the camizestrant combination versus 9.2 months for the comparator arm. Importantly, a consistent PFS benefit was observed across all CDK4/6 inhibitors and clinically relevant subgroups in the trial, including analysis by age, race, region, time of ESR1 mutation detection and type of ESR1 mutation.
The camizestrant combination was also associated with a meaningful delay in time to deterioration in quality of life, where in an exploratory endpoint, the camizestrant combination reduced the risk of deterioration in global health status and quality of life by 47% compared with the AI combination (HR 0.53; 95% CI, 0.33-0.82; nominal p<0.001). The median time to deterioration of global health status was 23.0 months in patients treated with the camizestrant combination, versus 6.4 months in patients that continued treatment with the AI combination (EORTC QLQ-C30). The camizestrant combination also delayed the time to deterioration of pain compared with the AI combination.
Data for the key secondary endpoints of time to second disease progression (PFS2) and overall survival (OS) were immature at the time of this interim analysis. However, a trend toward extended treatment benefit was observed with the camizestrant combination based on PFS2 (HR 0.52; 95% CI 0.33-0.81; p=0.0038 [interim analysis threshold p=0.0001]). The trial will continue to assess OS, PFS2 and other key secondary endpoints.
Nicholas Turner, MD, PhD, Professor of Molecular Oncology at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, London, UK, and co-principal investigator for the trial, said: "Today's news marks a pivotal moment in breast cancer care and redefines how we think about drug resistance in this type of breast cancer. The results of the innovative SERENA-6 trial show that switching from an aromatase inhibitor to camizestrant in combination with any of the three CDK4/6 inhibitors after emergence of an ESR1 mutation more than halved the risk of disease progression or death and delayed deterioration in quality of life by nearly 18 months. This proactive approach exemplifies a new treatment strategy in oncology; by treating developing resistance before it causes disease progression and deterioration in quality of life, we can extend the benefit of 1st-line treatment to optimize patient outcomes."
Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "As the first pivotal trial to demonstrate the clinical value of monitoring circulating tumor DNA to detect emerging resistance and change therapy at the earliest opportunity; SERENA-6 is redefining the clinical paradigm in breast cancer. Camizestrant is the first and only next-generation oral SERD and complete estrogen receptor antagonist to demonstrate benefit in combination with widely approved CDK4/6 inhibitors in this 1st-line setting, and these results support its potential as a new standard-of-care endocrine therapy backbone in the treatment of HR-positive breast cancer."
Summary of results: SERENA-6
Camizestrant + CDK4/6
inhibitor (n=155)
AI + CDK4/6 inhibitor
(n=155)
PFSi
Median PFS (months)
16.0 (12.7-18.2)
9.2 (7.2-9.5)
Hazard ratio (95% CI)
0.44 (0.31-0.60)
p-value
p<0.00001
Time to deterioration in global health status/quality of lifeii
Mean TTD (months)
23.0 (13.8-NC)
6.4 (2.8, 14.0)
Hazard ratio (95% CI)
0.53 (0.33-0.82)
p-value (nominal)
p<0.001
PFS2iii
Events
38
47
Hazard ratio (95% CI)
0.52 (0.33-0.81)
p-value
P=0.0038
[interim analysis threshold P=0.0001]
CI, confidence interval; HR, hazard ratio; NC, not calculable; TTD, time-to-deterioration.i PFS was defined per RECIST v1.1. HR was estimated using the Cox proportional hazard model adjusted for stratification factors.ii Assessments were conducted at baseline, weeks 4, 8 and 12 and then every 8 weeks until PFS2. Analysis conducted in patients with a baseline score and at least one post-baseline assessment. TTD in global health status/quality of life, an exploratory endpoint, was defined as the time from randomization to first deterioration that was confirmed at a subsequent timepoint measured using the European Organization for Research and Treatment of Cancer 30-item quality-of-life questionnaire (EORTC QLQ-30). Deterioration was defined as a decrease from baseline ≥16.6. HR was estimated using the Cox proportional hazard model stratified by time of ESR1 mutation detection (one test vs more than one test), and time from initiation of AI + CDK4/6i to randomization (<18 months vs. ≥18 months).iii HR was estimated using the Cox proportional hazard model adjusted for stratification factors. Final PFS2 analysis will occur at 158 PFS2 events.
The safety profile of camizestrant in combination with palbociclib, ribociclib or abemaciclib in SERENA-6 was consistent with the known safety profile of each medicine. Consistent with the longer duration of exposure to the combination of camizestrant and CDK4/6 inhibitors in the trial, Grade 3 or higher adverse events from all causes occurred in 60% of patients in the camizestrant arm versus 46% in the AI arm; the majority of which were hematological events typically associated with CDK4/6 inhibitor treatment and included neutropenia (45% vs. 34%), anemia (5% vs. 5%) and leukopenia (10% vs. 3%). If experienced, photopsia - reported as brief flashes of light in the peripheral vision - did not impact daily activities of patients in the trial and was reversible. There were no structural changes in the eye or changes in visual acuity. No new safety signals were identified and discontinuation rates were very low and similar in both arms, with 1% patients discontinuing camizestrant and 2% patients discontinuing an AI. Discontinuation of the CDK4/6 inhibitor occurred in 1% of patients in both arms of the trial.
SERENA-6 is the first global, double-blind, registrational Phase III trial to use a circulating tumor DNA (ctDNA)-guided approach to detect the emergence of endocrine resistance and inform a switch in therapy before disease progression. The novel trial design used ctDNA monitoring at the time of routine tumor scans to identify patients for early signs of endocrine resistance and the emergence of ESR1 mutations. Following detection of an ESR1 mutation without disease progression, the endocrine therapy of patients was switched to camizestrant from ongoing treatment with an AI, while continuing combination with the same CDK4/6 inhibitor.
Based on the results of the SERENA-6 Phase III trial, camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) has been granted Breakthrough Therapy Designation (BTD) in the US by the Food and Drug Administration for the treatment of adult patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer upon emergence of ESR1 mutation during first-line endocrine-based therapy.
Notes
HR-positive breast cancer
Breast cancer is the second most common cancer and one of the leading causes of cancer-related deaths worldwide.1 More than two million patients were diagnosed with breast cancer in 2022, with more than 665,000 deaths globally.1 While survival rates are high for those diagnosed with early breast cancer, only about 30% of patients diagnosed with or who progress to metastatic disease are expected to live five years following diagnosis.2
HR-positive breast cancer, characterized by the expression of estrogen or progesterone receptors, or both, is the most common subtype of breast cancer with 70% of tumors considered HR-positive and HER2-negative.2 ERs often drive the growth of HR-positive breast cancer cells.3
Globally, approximately 200,000 patients with HR-positive breast cancer are treated with a medicine in the 1st-line setting; most frequently with endocrine therapies that target estrogen receptor (ER)-driven disease, which are often paired with CDK4/6 inhibitors.4-6 However, resistance to CDK4/6 inhibitors and current endocrine therapies develops in many patients with advanced disease.6 Once this occurs, treatment options are limited and survival rates are low with 35% of patients anticipated to live beyond five years after diagnosis.2,6,7
Mutations in the ESR1 gene are a key driver of endocrine resistance and are widely tested for in clinical practice at time of disease progression on 1st-line therapies.8,9 These mutations emerge during treatment of the disease, becoming more prevalent as the disease progresses and are associated with poor outcomes.8,9 Approximately 30% of patients with endocrine sensitive HR-positive disease develop ESR1 mutations during 1st-line treatment without disease progression.4
The optimization of endocrine therapy and overcoming resistance to enable patients to continue benefiting from these treatments, as well as identifying new therapies for those who are less likely to benefit, are active areas of focus for breast cancer research.
SERENA-6
SERENA-6 is a Phase III, double-blind, randomized trial evaluating the efficacy and safety of camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) in patients with HR-positive, HER2-negative advanced breast cancer (patients with either locally advanced disease, or metastatic disease) whose tumors have an emergent ESR1 mutation.
The global trial enrolled 315 adult patients with histologically confirmed HR-positive, HER2-negative advanced breast cancer, undergoing treatment with an AI in combination with a CDK4/6 inhibitor as 1st-line treatment. The primary endpoint of the SERENA-6 trial is PFS as assessed by investigator, with secondary endpoints including OS, and PFS2 by investigator assessment.
Camizestrant
Camizestrant is an investigational, potent, next-generation oral selective estrogen receptor degrader (SERD) and complete ER antagonist that is currently in Phase III trials for the treatment of HR-positive breast cancer.
AstraZeneca's broad, robust and innovative clinical development program, including the SERENA-6, SERENA-4, CAMBRIA-1 and CAMBRIA-2 trials, is evaluating the safety and efficacy of camizestrant when used as a monotherapy or in combination with CDK4/6 inhibitors to address a number of areas of unmet need in HR-positive, HER2-negative breast cancer.
Camizestrant has demonstrated anti-cancer activity across a range of preclinical models, including those with ER-activating mutations. In the SERENA-2 Phase II trial, camizestrant demonstrated PFS benefit versus fulvestrant irrespective of ESR1 mutation status or prior treatment with CDK4/6 inhibitors in patients with ER-positive locally advanced or metastatic breast cancer, previously treated with endocrine therapy. The SERENA-1 Phase I trial demonstrated that camizestrant is well tolerated and has a promising anti-tumor profile when administered alone or in combination with palbociclib, ribociclib and abemaciclib; three widely used CDK4/6 inhibitors.
AstraZeneca in breast cancer
Driven by a growing understanding of breast cancer biology, AstraZeneca is challenging, and redefining, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need – with the bold ambition to one day eliminate breast cancer as a cause of death.
AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumor environment.
With fam-trastuzumab deruxtecan-nxki, a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive, HER2-low and HER2-ultralow metastatic breast cancer, and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines fulvestrant and goserelin and aims to reshape the HR-positive space with first-in-class AKT inhibitor, capivasertib, the TROP-2-directed ADC, datopotamab deruxtecan-dlnk and next-generation oral SERD and potential new medicine camizestrant.
PARP inhibitor olaparib is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with Merck & Co., Inc. (MSD outside the US and Canada) continue to research olaparib in these settings and to explore its potential in earlier disease. AstraZeneca is also exploring the potential of saruparib, a potent and selective inhibitor of PARP1, in combination with camizestrant in BRCA-mutated, HR-positive, HER2-negative advanced breast cancer.
To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is collaborating with Daiichi Sankyo to evaluate the potential of datopotamab deruxtecan-dlnk alone and in combination with immunotherapy durvalumab.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyze changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca.
References
Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024 Apr 4. doi: 10.3322/caac.21834.
National Cancer Institute. Cancer Stat facts: Female breast cancer subtypes. Available at: https://seer.cancer.gov/statfacts/html/breast-subtypes.html. Accessed June 2025.
Scabia V, et al. Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor. Nat Commun. 2022; 10.1038/s41467-022-30898-0.
Cerner CancerMPact database. Accessed June 2025.
Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer. J Cancer. 2020; 10.7150/jca.48944.
Lloyd M R, et al. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities. Clin Cancer Res. 2022; 28(5):821-30.
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology (NCCN Guidelines). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed June 2025.
Brett O, et al. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor‑positive breast cancer. Breast Cancer Res. 2021; 23:85.
Zundelevich, A, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020; 22:16.
US-101612Last updated 06/25
View source version on businesswire.com: https://www.businesswire.com/news/home/20250601316083/en/
Contacts
Media Inquiries
Fiona Cookson +1 212 814 3923Jillian Gonzales +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
AstraZeneca announces $50B of investment in U.S. by 2030
AstraZeneca (AZN) announces $50B of investment in the United States by 2030, building on America's global leadership in medicines manufacturing and R&D. This investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the country powering growth and delivering next generation medicines for patients in America and worldwide. The cornerstone of this landmark investment is a new multi-billion dollar U.S. manufacturing facility that will produce drug substances for the company's innovative weight management and metabolic portfolio, including oral GLP-1, baxdrostat, oral PCSK9 and combination small molecule products. The new state-of-the-art center will produce small molecules, peptides and oligonucleotides. This multi-billion dollar capital investment is in addition to the $3.5B announced in November 2024. The drug substance facility, planned to be in the Commonwealth of Virginia, would be AstraZeneca's largest single manufacturing investment in the world. The facility will leverage AI, automation, and data analytics to optimize production. 'The $50B investment across our R&D and manufacturing footprint in the US over the next five years also includes: Expansion of our R&D facility in Gaithersburg, Maryland; State-of-the-art R&D center in Kendall Square, Cambridge, Massachusetts; Next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; Continuous manufacturing expansion in Mount Vernon, Indiana; Specialty manufacturing expansion in Coppell, Texas; New sites to supply clinical trials. Our growing research and development investment in novel medicines. Collectively, these investments will help deliver AstraZeneca's ambition of reaching $80B in Total Revenue by 2030, of which we expect 50% would be generated in the U.S.' Elevate Your Investing Strategy:
Yahoo
an hour ago
- Yahoo
Protocol flexibility and navigating the US geopolitical landscape in oncology clinical trials
Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible. At the Clinical Trials in Oncology (CTO) East Coast conference, which took place between 8 and 9 July in Boston, US, key themes under consideration included strategies to account for the shifting geopolitical landscape in the US and beyond, budgeting effectively for an oncology clinical trial, trial design best practices, and augmenting trials with technology to shorten timelines and reduce costs. Accounting for the current geopolitical landscape With economic challenges, such as the Trump administration's imposition of tariffs, biotechs are facing mounting capital challenges that influence clinical trial activity. During a panel on the evolving oncology trials landscape in the US, speakers reflected on how to navigate this shifting landscape effectively. AstraZeneca's executive director of oncology regulatory strategy Shaily Arora advised keeping the global development strategy in mind, noting that it may be helpful to work with CROs that have specialisation in European regulation, given that regulation such as the EU's clinical trials regulation (CTR) is quite different in comparison to US regulatory requirements. Beth Chamblin, senior director, project management, late phase oncology at IQVIA Biotech, highlighted that trust, flexibility, and early integration have become foundational, and that policy advocacy is becoming increasingly more important with respect to navigating changes. The panellists also agreed that regional diversification was of rising importance in planning, for example, flexible trial designs, so that if something does change [in the US], there is a backup option to continue a clinical trial, pivoting if required. The importance of flexible trial protocol design During an interview with Clinical Trials Arena, NextPoint Therapeutics' chief medical officer Leena Gandhi stressed how flexible trial designs can shorten study timelines and decrease costs. A key aspect Gandhi homed in on was being aware when moving 'operationally slowly' through dose escalation in Phase I, positing this as one area that can stymy a trial's movement into Phase III. 'It's challenging from both a patient and clinician point of view to put patients on sub-therapeutic doses,' Gandhi says. 'There's a tendency to say, let's wait and see, especially if there's a large dose range, to get into those higher doses.' 'The more a trial's design focuses on using biology to minimise the dose levels that are chosen, the faster we can at least move through the dose evaluation, which represents one of the biggest challenges of spending too much time in Phase I.' However, Gandhi added that learning as much as possible during Phase I can serve to expedite oncology clinical trials, potentially making it possible to 'skip' a Phase II trial and progress to Phase III sooner. She commented: 'The more solidly we can understand both the right dose as well as the right patient selection strategy before Phase III, the bigger the impact will be, the bigger the difference in outcomes between the control arm in a randomised setting, and the faster you'll get through that Phase III trial, because you'll have a body of robust data before getting there.' While advocating for the creation of adaptable trial designs that allow for flexibility during trials for increased efficiency, Gandhi pointed out that being too flexible can also be a pitfall. Gandhi explains: 'You can spend a lot of time writing vague language in a protocol and then have it not be approved by the regulatory authorities because it's too vague. And at some level, you can't predict everything you're going to learn in a Phase I trial, either. You can't anticipate all the different things that you might need to do. You have to be able to respond to the data. 'One thing I hope we're moving towards, from a regulatory environment perspective, is getting faster and better at amending trials if we need to, so we don't lose time, because it's hard to know everything that you might run into ahead of time.' Patient-centricity is key Speakers also focused on how clinical trials can be made more amenable for patients. The prevailing theme was that patient centricity is key, and that success in oncology trials, given the gravitas of patients living with cancer, foremostly needs to meet patients where they are. To ensure patient retention in trials and mitigate drop-out rates, various speakers advised that trials should be designed with geographic location and patient convenience as the utmost considerations. Meanwhile, in certain cases and to the extent possible, attendees were advised to augment their oncology clinical trials with technology such as AI and remote patient monitoring tools to hasten and simplify measurement protocols where possible. Finally, with trial design, attendees were advised to plan to ensure there are no surprises later in the study to maximise the success of a trial with as high a participation rate as possible. Other sessions, including one led by Kelly Schlemm, vice-president and head of corporate affairs at Servier Pharmaceuticals, outlined the best approaches towards raising community awareness of oncology trials to boost participation. Schlemm's advice included leaning on patient advocacy groups to raise clinical trial awareness – a matter of particular importance for isolated or remote rural communities where there has historically been a scarcity of clinical trials. AstraZeneca's Shaily Arora reflected on the US Food and Drug Administration's (FDA) priority review programmes, such as the breakthrough therapy and fast track designation programmes, and how they can streamline developmental timelines, leading to faster drug approvals and thereby meeting patient needs earlier. In an interview with Clinical Trials Arena, Arora notes that there is a 'threshold of information' required for companies to show that they are offering something better than what is currently available when seeking approval for such programmes. Arora advises: 'Having a long-term plan, so engaging with the healthcare authorities early on to devise the strategy for your early phase clinical trials, utilising and optimising early phase trials to leverage the data that you need to help successful late phase trials, will be very beneficial. 'These designations can give you the opportunity to have that open dialogue and frequent communication with the health authority. That could be one way to streamline the development and design studies that are fit for purpose.' Hopes around AI Another key theme of the conference was the potential of AI to expedite trials, gain fresh insights, or hasten development timelines. During a panel session featuring speakers including Rebecca Jacob, project lead of clinical and global study management at Sanofi, panel members expressed their hopes that AI would over time play an increased role in managing data and quality, selecting the most suitable patients for trials, and reaching patients in remote rural areas by analysing their electronic healthcare records (EHR) to gauge trial participation suitability. However, panellists agreed that when thinking about AI, companies should evaluate what's most challenging for them and what may adequately be remedied with AI, rather than 'going with the trend' and implementing AI without due consideration. The speakers concurred that AI deployment should be centred around building efficiencies to allow everyone in an organisation to perform their jobs better or faster, rather than thinking about AI as a means of replacing the human workforce. "Protocol flexibility and navigating the US geopolitical landscape in oncology clinical trials" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
KIOXIA Announces Industry's First 245.76 TB NVMe SSD Built for the Demands of Generative AI Environments
SAN JOSE, Calif.--(BUSINESS WIRE)-- KIOXIA America, Inc. has expanded its high-capacity KIOXIA LC9 Series enterprise SSD lineup by introducing the industry's first 1 245.76 terabyte (TB) 2 NVMe™ SSD in a 2.5-inch and Enterprise and Datacenter Standard Form Factor (EDSFF) E3.L form factor. This new capacity and form factor option complements the previously announced 122.88 TB (2.5-inch) model and is purpose-built for the performance and efficiency demands of generative AI environments. 'As generative AI reshapes data center architecture, we're delivering the kind of breakthrough technology that enables our customers to optimize their IT infrastructure investments - pushing boundaries in performance, efficiency, and scale.' Generative AI places unique demands on storage, including the need to store vast datasets for training large language models (LLMs), and to create embeddings and vector databases that support inference through retrieval augmented generation (RAG). These workloads require storage solutions with large capacity, high speed, and exceptional power efficiency. Featuring a 32-die stack of 2 terabit (Tb) 3 BiCS FLASH™ QLC 3D flash memory with innovative CBA (CMOS directly Bonded to Array) technology, KIOXIA LC9 Series SSDs deliver the speed, scale, and density required to support the next wave of AI-centric workloads. This combination of advanced memory architecture and CBA technology enables 8 TB 3 in a small 154 BGA package – also an industry first 1. This milestone was made possible with advancements in Kioxia's high-precision wafer processing, material design, and wire bonding technologies. KIOXIA LC9 Series SSDs are well-suited for data lakes, where massive data ingestion and rapid processing are essential. Unlike HDDs, which often bottleneck performance and leave costly GPUs underutilized, KIOXIA LC9 Series SSDs enable dense storage in a compact footprint. By delivering up to 245.76 TB, each drive can replace multiple power-hungry HDDs, offering superior performance, lower overall power consumption, fewer drive slots used, and more efficient cooling, which would significantly lower total cost of ownership (TCO). KIOXIA LC9 Series SSDs Features Include: Up to 245.76 TB in 2.5-inch and E3.L form factors Up to 122.88 TB available in 2.5-inch and E3.S form factors Designed to PCIe ® 5.0 (max. 128 GT/s Gen5 single x4, dual x2), NVMe 2.0, and NVMe-MI™ 1.2c specifications Open Compute Project (OCP) Datacenter NVMe SSD specification v2.5 support (not all requirements) Flexible Data Placement (FDP) support to minimize write amplification and extend SSD lifespan 4 Security options: SIE, SED, FIPS SED CNSA 2.0 signing algorithm adopted 5, designed with future quantum security standards in mind 'KIOXIA has a long history of advancing flash storage, and the KIOXIA LC9 Series continues that legacy by setting a new benchmark for capacity and innovation in the SSD space,' said Neville Ichhaporia, senior vice president and general manager of the SSD business unit at KIOXIA America, Inc. 'As generative AI reshapes data center architecture, we're delivering the kind of breakthrough technology that enables our customers to optimize their IT infrastructure investments - pushing boundaries in performance, efficiency, and scale.' KIOXIA LC9 Series SSDs are now sampling to select customers and will be featured at the Future of Memory and Storage 2025 conference, taking place August 5–7 in Santa Clara. For more information, please visit and follow the company on X, formerly known as Twitter and LinkedIn ®. About KIOXIA America, Inc. KIOXIA America, Inc. is the U.S.-based subsidiary of KIOXIA Corporation, a leading worldwide supplier of flash memory and solid-state drives (SSDs). From the invention of flash memory to today's breakthrough BiCS FLASH™ 3D technology, KIOXIA continues to pioneer innovative memory, SSD and software solutions that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. For more information, please visit © 2025 KIOXIA America, Inc. All rights reserved. Information in this press release, including product pricing and specifications, content of services, and contact information is current and believed to be accurate on the date of the announcement, but is subject to change without prior notice. Technical and application information contained here is subject to the most recent applicable KIOXIA product specifications. Notes: 1: As of July 21, 2025, based on Kioxia survey. 2: Definition of SSD capacity: Kioxia Corporation defines a kilobyte (KB) as 1,000 bytes, a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes, a terabyte (TB) as 1,000,000,000,000 bytes, and a kibibyte (KiB) is 1,024 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary. 3: The flash memory capacity is calculated as 1 terabit (1 Tb) = 1,099,511,627,776 (2^40) bits, and 1 terabyte (1 TB) = 1,099,511,627,776 (2^40) bytes. 4: For RocksDB purposes, Kioxia confirmed the Write Amplification Factor (WAF) is approximately 1.1 when using the FDP function with the plug-in (a function extension program released on the Kioxia GitHub account. 5: The KIOXIA LC9 Series SSD supports Leighton-Micali Signature (LMS) algorithm acknowledged by CNSA 2.0 (Commercial National Security Algorithm Suite 2.0) as a digital signature algorithm to prevent firmware tampering in preparation for threats to conventional cryptographic algorithms posed by quantum computers. Advanced Encryption Standard (AES-256) with a key length of 256 bits, which is the data encryption algorithm used in KIOXIA LC9 Series SSD, is also acknowledged by CNSA 2.0. 2.5-inch indicates the form factor of the SSD and not its physical size. Read and write speed may vary depending on various factors such as host devices, software (drivers, OS etc.), and read/write conditions. NVMe and NVMe-MI are registered or unregistered trademarks of NVM Express, Inc. in the United States and other countries. PCIe is a registered trademark of PCI-SIG. The OCP and OPEN COMPUTE PROJECT marks are owned by and used with the permission of the Open Compute Project Foundation. Sanitize Instant Erase (SIE), Self-Encrypting Drive (SED) and FIPS (Federal Information Processing Standards) SED security optional models are available. Security optional models are not available in all countries due to export and local regulations. LinkedIn is a trademark of LinkedIn Corporation and its affiliates in the United States and/or other countries. Other company names, product names and service names may be trademarks of third-party companies.
